267 related articles for article (PubMed ID: 18557712)
1. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review.
Gisbert JP; Gomollón F
Am J Gastroenterol; 2008 Jul; 103(7):1783-800. PubMed ID: 18557712
[TBL] [Abstract][Full Text] [Related]
2. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
[TBL] [Abstract][Full Text] [Related]
3. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis.
Bermejo F; Lopez-Sanroman A; Taxonera C; Gisbert JP; Pérez-Calle JL; Vera I; Menchén L; Martín-Arranz MD; Opio V; Carneros JA; Van-Domselaar M; Mendoza JL; Luna M; López P; Calvo M; Algaba A
Aliment Pharmacol Ther; 2008 Sep; 28(5):623-8. PubMed ID: 18513380
[TBL] [Abstract][Full Text] [Related]
4. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
[TBL] [Abstract][Full Text] [Related]
5. Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease.
Disanti W; Rajapakse RO; Korelitz BI; Panagopoulos G; Bratcher J
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1025-9. PubMed ID: 16765651
[TBL] [Abstract][Full Text] [Related]
6. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
Banerjee S; Bishop WP
J Pediatr Gastroenterol Nutr; 2006 Sep; 43(3):324-30. PubMed ID: 16954954
[TBL] [Abstract][Full Text] [Related]
7. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
8. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
Gearry RB; Barclay ML; Burt MJ; Collett JA; Chapman BA
Pharmacoepidemiol Drug Saf; 2004 Aug; 13(8):563-7. PubMed ID: 15317038
[TBL] [Abstract][Full Text] [Related]
9. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
10. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease.
López-Martín C; Chaparro M; Espinosa L; Bejerano A; Maté J; Gisbert JP
Gastroenterol Hepatol; 2011; 34(6):385-92. PubMed ID: 21616565
[TBL] [Abstract][Full Text] [Related]
11. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
[TBL] [Abstract][Full Text] [Related]
12. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease.
Tajiri H; Tomomasa T; Yoden A; Konno M; Sasaki M; Maisawa S; Sumazaki R; Shimizu T; Toyoda S; Etani Y; Nakacho M; Ushijima K; Kobayashi A;
Digestion; 2008; 77(3-4):150-4. PubMed ID: 18577852
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of low dose azathioprine/6-mercaptopurine in patients with inflammatory bowel disease.
Kim DU; Kim YH; Kim BJ; Chang DK; Son HJ; Rhee PL; Kim JJ; Rhee JC
Hepatogastroenterology; 2009; 56(94-95):1395-402. PubMed ID: 19950798
[TBL] [Abstract][Full Text] [Related]
15. More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing.
Broekman MMTJ; Coenen MJH; van Marrewijk CJ; Wanten GJA; Wong DR; Verbeek ALM; Klungel OH; Hooymans PM; Guchelaar HJ; Scheffer H; Derijks LJJ; de Jong DJ;
Inflamm Bowel Dis; 2017 Oct; 23(10):1873-1881. PubMed ID: 28644183
[TBL] [Abstract][Full Text] [Related]
16. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Cao Q; Zhu Q; Shang Y; Gao M; Si J
Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
[TBL] [Abstract][Full Text] [Related]
17. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.
Seidman EG
Rev Gastroenterol Disord; 2003; 3 Suppl 1():S30-8. PubMed ID: 12684587
[TBL] [Abstract][Full Text] [Related]
18. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.
Gao X; Zhang FB; Ding L; Liu H; Wang XD; Chen BL; Bi HC; Xiao YL; Zhao LZ; Chen MH; Huang M; Hu PJ
Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):958-64. PubMed ID: 22664938
[TBL] [Abstract][Full Text] [Related]
19. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine.
Seksik P; Cosnes J; Sokol H; Nion-Larmurier I; Gendre JP; Beaugerie L
Aliment Pharmacol Ther; 2009 May; 29(10):1106-13. PubMed ID: 19222411
[TBL] [Abstract][Full Text] [Related]
20. Review article: thiopurines in inflammatory bowel disease.
Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
